Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $68

Benzinga · 11/26 12:58
Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $56 to $68.